Intangibles and the Market Value of Biopharmaceutical Startups
Abstract
This paper investigates the relationship between various measures of intangible capital and the market valuation of young biopharmaceutical firms. We employ a non-linear model to measure the impact of R&D, patents, alliances, organizational capital, and mergers on the value of 349 newly-incorporated firms between 1980 and 2006. We find that, with the exception of mergers, our measures of intangible capital have positive and significant effects on market values; the impact of R&D declines as firms mature; and the omission of either alliances or organizational capital leads to a significant overstatement of the influence of R&D.
Published
2019-01-28
How to Cite
MORALES, Rosa; RADONIQI, Fatos.
Intangibles and the Market Value of Biopharmaceutical Startups.
The Journal of Business Inquiry, [S.l.], v. 18, n. 2, p. 82-99, jan. 2019.
ISSN 2155-4072.
Available at: <https://journals.uvu.edu/index.php/jbi/article/view/292>. Date accessed: 26 june 2022.
Section
Articles